Inducible nitric oxide synthase protection against Coxsackievirus pancreatitis

Journal of Immunology

Volumn 163, Issue 10, 1999, Pages 5497-5504

  Zaragoza, Carlos ^a   Ocampo, Christopher J ^a   Saura, Marta ^a   Bao, Clare ^a   Leppo, Michelle ^a   Lafond Walker, Anne ^a   Thiemann, David R ^a   Hruban, Ralph ^a   Lowenstein, Charles J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; HOST RESISTANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; COXSACKIEVIRUS INFECTIONS; ENCEPHALITIS, VIRAL; ENTEROVIRUS B, HUMAN; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDITIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PANCREAS; PANCREATITIS;

EID: 0033571461     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Ray, C. G. 1994. Enteroviruses and reoviruses. In Harrison's Principles of Internal Medicine, 13th Ed. K. J. Isselbacher, E. Braunwald, J. D. Wilson, J. B. Martin, A. S. Fauci, and D. L. Kasper, eds. McGraw-Hill, New York, p. 821.
2. Woodruff, J. F. 1980. Viral myocarditis: a review. Am. J. Pathol. 101:425.
3. Herskowitz, A., and A. Ahmed-Ansari. 1993. Myocarditis. Curr. Opin. Cardiol. 8:473.
4. Moore, M., M. Kaplan, J. McPhee, D. Bregman, and S. Klein. 1984. Epidemiologic, clinical, and laboratory features of coxsackie B1-B5 infections in the United States. Pub. Health Rep. 99:515.
5. Leslie, K., R. Blay, C. Haisch, A. Lodge, A. Weller, and S. Huber. 1989. Clinical and experimental aspects of viral myocarditis. Clin. Microbiol. Rev. 2:196.
6. Gooby Toedt, D. M., J. C. Byrd, and D. Omori. 1996. Coxsackievirus-associated pancreatitis mimicking metastatic carcinoma. South. Med. J. 89:441.
7. Hartig, P. C., and S. R. Webb. 1983. Heterogeneity of a human isolate of Coxsackie B4: biological differences. J. Infect. 6:43.
8. Laszik, Z. G., M. Kallajoki, T. Hyypia, B. Rima, H. J. Aho, and T. J. Nevalainen. 1990. Mumps, enteroviruses, and human acute pancreatitis. Scand. J. Gastroenterol. 25:906.
9. Ramsingh, A. I. 1997. Coxsackievirus and pancreatitis. Front. Biosci. 2:e53.
10. + cells initiate both myocarditis and pancreatitis in DBA/2 mice. Am. J. Pathol. 135:899.
11. Vuorinen, T., M. Kallajoki, T. Hyypia, and R. Vainionpaa. 1989. Coxsackievirus B3-induced acute pancreatitis: analysis of histopathological and viral parameters in a mouse model. Br. J. Exp. Pathol. 70:395.
12. Gomez, R. M., E. F. Lascano, and M. I. Berria. 1991. Murine acinar pancreatitis preceding necrotizing myocarditis after Coxsackievirus B3 inoculation. J. Med. Virol. 35:71.
13. Tsui, C. Y., G. E. Burch, and J. M. Harb. 1972. Pancreatitis in mice infected with Coxsackievirus B1. Arch. Pathol. 93:379.
14. Smith, R., and R. Deibel. 1975. Coxsackievirus infection in mice. Arch. Intern. Med. 135:238.
15. Lansdown, A. B. 1976. Pathological changes in the pancreas of mice following infection with coxsackie B viruses. Br. J. Exp. Pathol. 57:331.
16. Vella, C., and H. Festenstein. 1992. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. J. Gen. Virol. 73:1379.
17. Arola, A., H. Kalimo, O. Ruuskanen, and T. Hyypia. 1995. Experimental myocarditis induced by two different Coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J. Med. Virol. 47:251.
18. Gomez, R. M., J. J. Lopez Costa, G. Pecci Saavedra, and M. I. Berria. 1993. Ultrastructural study of cell injury induced by Coxsackievirus B3 in pancreatic and cardiac tissues. Medicina 53:300.
19. Zhang, H., G. E. Yousef, X. Ouyang, and L. C. Archard. 1994. Characterization of a murine model of myocarditis induced by a reactivated Coxsackievirus B3. Int. J. Exp. Pathol. 75:99.
20. Chow, L. H., K. W. Beisel, and B. M. McManus. 1992. Enteroviral infection of mice with severe combined immunodeficiency: evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66:24.
21. Huber, S. A., and L. P. Job. 1983. Cellular immune mechanisms in Coxsackievirus group B, type 3 induced myocarditis in BALB/c mice. Adv. Exp. Med. Biol. 161:491.
22. Huber, S. A., L. P. Job, and J. F. Woodruff. 1980. Lysis of infected myofibers by Coxsackievirus B-3-immune T lymphocytes. Am. J. Pathol. 98:681.
23. + cytolytic lymphocytes. Cell. Immunol. 88:558.
24. Huber, S. A., A. Moraska, and M. Choate. 1992. T cells expressing the γδ T-cell receptor potentiate Coxsackievirus B3-induced myocarditis. J. Virol. 66:6541.
25. Leipner, C., M. Borchers, I. Merkle, and A. Stelzner. 1999. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. J. Hum. Virol. 2:102.
26. Ramsingh, A. I., W. T. Lee, D. N. Collins, and L. E. Armstrong. 1999. T cells contribute to disease severity during Coxsackievirus B4 infection. J. Virol. 73: 3080.
27. Seko, Y., N. Takahashi, M. Azuma, H. Yagita, K. Okumura, and Y. Yazaki. 1998. Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies. Circ. Res. 83:463.
28. Cook, D. N., M. A. Beck, T. M. Coffman, S. L. Kirby, J. F. Sheridan, I. B. Pragnell, and O. Smithies. 1995. Requirement of MIP-1α for an inflammatory response to viral infection. Science 269:1583.
29. Gebhard, J. R., C. M. Perry, S. Harkins, T. Lane, I. Mena, V. C. Asensio, I. L. Campbell, and J. L. Whitton. 1998. Coxsackievirus B3-induced myocarditis: perform exacerbates disease, but plays no detectable role in virus clearance. Am. J. Pathol. 153:417.
30. Godeny, E. K., and C. J. Gauntt. 1986. Involvement of natural killer cells in Coxsackievirus B3 induced murine myocarditis. J. Immunol. 137:1695.
31. Godeny, E. K., and C. J. Gauntt. 1987. Murine natural killer cells limit Coxsackievirus B3 replication. J. Immunol. 139:913.
32. Ramsingh, A. I., W. T. Lee, D. N. Collins, and L. E. Armstrong. 1997. Differential recruitment of B and T cells in Coxsackievirus B4-induced pancreatitis is influenced by a capsid protein. J. Virol. 71:8690.
33. + T-cell receptor. J. Virol. 70:3039.
34. Cook, D. N. 1996. The role of MIP-1α in inflammation and hematopoiesis. J. Leukocyte Biol. 59:61.
35. Bendinelli, M., D. Matteucci, A. Toniolo, A. M. Patane, and M. P. Pistillo. 1982. Impairment of immunocompetent mouse spleen cell functions by infection with Coxsackievirus B3. J. Infect. Dis. 146:797.
36. Woodruff, J. F. 1979. Lack of correlation between neutralizing antibody production and suppression of Coxsackievirus B3 replication in target organs: evidence for the involvement of mononuclear inflammatory cells in defense. J. Immunol. 123:31.
37. Godeny, E. K., and C. J. Gauntt. 1987. In situ immune autoradiographic identification of cells in heart tissues of mice with Coxsackievirus B3-induced myocarditis. Am. J. Pathol. 129:267.
38. Woodruff, J. F., and J. J. Woodruff. 1974. Involvement of T lymphocytes in the pathogenesis of Coxsackievirus B3 heart disease. J. Immunol. 113:1726.
39. Heim, A., M. Stille-Seigener, P. Pring-Akerblom, I. Grumbach, C. Brehm, H. Kreuzer, and H. R. Figulla. 1996. Recombinant interferons β and γ have a higher antiviral activity than interferon-α in Coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. J. Interferon Cytokine Res. 16: 283.
40. Hiraoka, Y., C. Kishimoto, H. Takada, M. Nakamura, M. Kurokawa, H. Ochiai, and K. Shiraki. 1996. Nitric oxide and murine Coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase. J. Am. Coll. Cardiol. 28:1610.
41. Okada, I., A. Matsumori, Y. Matoba, M. Tominaga, T. Yamada, and C. Kawai. 1992. Combination treatment with ribavirin and interferon for Coxsackievirus B3 replication. J. Lab. Clin. Med. 120:569.
42. Heim, A., A. Canu, P. Kirschner, T. Simon, G. Mall, P. H. Hofschneider, and R. Kandolf. 1992. Synergistic interaction of interferon-β and interferon-γ in Coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166:958.
43. Capobianchi, M. R., D. Matteucci, A. Giovannetti, E. Soldaini, M. Bendinelli, J. G. Stanton, and F. Dianzani. 1991. Role of interferon in lethality and lymphoid atrophy induced by Coxsackievirus B3 infection in mice. Viral Immunol. 4:103.
44. Langford, M. P., R. M. Kadi, J. P. Ganley, and M. Yin-Murphy. 1988. Inhibition of epidemic isolates of Coxsackievirus type A 24 by recombinant and natural interferon α and interferon β. Intervirology 29:320.
45. Matsumori, A., N. Tomioka, and C. Kawai. 1988. Protective effect of recombinant α interferon on Coxsackievirus B3 myocarditis in mice. Am. Heart J. 115: 1229.
46. Kandolf, R., A. Canu, and P. H. Hofschneider. 1985. Coxsackie B3 virus can replicate in cultured human fetal heart cells and is inhibited by interferon. J. Mol. Cell. Cardiol. 17:167.
47. Horwitz, M. S., T. Krahl, C. Fine, J. Lee, and N. Sarvetnick. 1999. Protection from lethal Coxsackievirus-induced pancreatitis by expression of γ interferon. J. Virol. 73:1756.
48. Moncada, S., R. M. Palmer, and E. A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:109.
49. Knowles, R. G., and S. Moncada. 1994. Nitric oxide synthases in mammals. Biochem. J. 298:249.
50. Mannick, J. B. 1995. The antiviral role of nitric oxide. Res. Immunol. 146:693.
51. Nathan, C. 1997. Inducible nitric oxide synthase: what difference does it make? J. Clin. Invest. 100:2417.
52. Fang, F. C. 1997. Mechanisms of nitric oxide related antimicrobial activity. J. Clin. Invest. 99:2818.
53. Reiss, C. S., and T. Komatsu. 1998. Does nitric oxide play a critical role in viral infections? J. Virol. 72:4547.
54. Tucker, P. C., D. E. Griffin, S. Choi, N. Bui, and S. Wesselingh. 1996. Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. J. Virol. 70:3972.
55. Akarid, K., M. Sinet, B. Desforges, and M. A. Gougerot-Pocidalo. 1995. Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J. Virol. 69:7001.
56. Akaike, T., Y. Noguchi, S. Ijiri, K. Setoguchi, M. Suga, Y. M. Zheng, B. Dietzschold, and H. Maeda. 1996. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA 93:2448.
57. Kreil, T. R., and M. M. Eibl. 1996. Nitric oxide and viral infection: NO antiviral activity against a flavivirus in vitro, and evidence for contribution to pathogenesis in experimental infection in vivo. Virology 219:304.
58. Lowenstein, C. J., S. L. Hill, A. Lafond-Walker, J. Wu, G. Allen, M. Landavere, N. R. Rose, and A. Herskowitz. 1996. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 97:1837.
59. Mikami, S., S. Kawahima, K. Kanazawa, K. I. Hirata, H. Hotta, Y. Hayashi, H. Itoh, and M. Yokoyama. 1997. Low-dose nitro-arginine methyl ester treatment improves survival rate and decreases myocardial injury in a murine model of viral myocarditis induced by Coxsackievirus B3. Circ. Res. 81:504.
60. Nathan, C. 1995. Natural resistance and nitric oxide. Cell 82:873.
61. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. 162:156.
62. Klump, W. M., I. Bergmann, B. C. Muller, D. Ameis, and R. Kandolf. 1990. Complete nucleotide sequence of infectious Coxsackievirus B3 cDNA: two initial 5′ uridine residues are regained during plus-strand RNA synthesis. J. Virol. 64: 1573.
63. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1991. Current Protocols in Molecular Biology. John Wiley and Sons, New York.
64. Samuel, I., Y. Toriumi, D. P. Wilcockson, C. M. Turkelson, T. E. Solomon, and R. J. Joehl. 1995. Bile and pancreatic juice replacement ameliorates early ligation-induced acute pancreatitis in rats. Am. J. Surg. 169:391.
65. Karupiah, G., J. H. Chen, S. Mahalingam, C. F. Nathan, and J. D. MacMicking. 1998. Rapid interferon γ-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. J. Exp. Med. 188:1541.
66. Croen, K. D. 1993. Evidence for antiviral effect of nitric oxide: inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91:2446.
67. Karupiah, G., Q. W. Xie, R. M. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. 1993. Inhibition of viral replication by interferon-γ-induced nitric oxide synthase. Science 261:1445.
68. Bi, Z., and C. S. Reiss. 1995. Inhibition of vesicular stomatitis virus infection by nitric oxide. J. Virol. 69:2208.
69. Rolph, M. S., I. A. Ramshaw, K. A. Rockett, J. Ruby, and W. B. Cowden. 1996. Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. Virology 217:470.
70. Butz, E A., B. S. Hostager, and P. J. Southern. 1994. Macrophages in mice acutely infected with lymphocytic choriomeningitis virus are primed for nitric oxide synthesis. Microb. Pathog. 16:283.
71. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, C. J. Feng, F. P. Huang, D. M. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408.
72. MacMicking, J. D., C. Nathan, G. Hom, N. Chartrain, D. S. Fletcher, M. Traumbauer, K. Stevens, Q. W. Xie, K. Sokol, N. Hutchinson, H. Chen, and I. S. Mudgett. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641.
73. Karupiah, G., J. H. Chen, C. F. Nathan, S. Mahalingam, and J. D. MacMicking. 1998. Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection. J. Virol. 72:7703.
74. Saura, M., Zaragoza, C., McMillan, A., Quick, R. A., Hohenadl, C., Lowenstein, J. M., and Lowenstein, C. J. 1999. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10:21.
75. Diefenbach, A., H. Schindler, N. Donhauser, E. Lorenz, T. Laskay, J. MacMicking, M. Rollinghoff, I. Gresser, and C. Bogdan. 1998. Type 1 interferon (IFNα/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8:77.
76. Stamler, J. S., D. J. Singel, and J. Loscalzo. 1992. Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898.
77. Beckman, J. S., T. W. Beckman, J. Chen, P. A. Marshall, and B. A. Freeman. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87:1620.
78. Stamler, J. S. 1994. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78:931.
79. Zaragoza, C., C. J. Ocampo, M. Saura, A. McMillan, and C. J. Lowenstein. 1997. Nitric oxide inhibition of Coxsackievirus replication in vitro. J. Clin. Invest. 100:1760.
80. Harris, N., R. M. Buller, and G. Karupiah. 1995. γ Interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:910.
81. Mannick, J. B., K. Asano, K. Izumi, E. Kieff, and J. S. Stamler. 1994. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79:1137.
82. Schwarz, E. M., C. Badorff, T. S. Hiura, R. Wessely, A. Badorff, I. M. Verma, and K. U. Knowlton. 1998. NF-κB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J. Virol. 72:5654.
83. Carthy, C. M., D. J. Granville, K. A. Watson, D. R. Anderson, J. E. Wilson, D. Yang, D. W. Hunt, and B. M. McManus. 1998. Caspase activation and specific cleavage of substrates after Coxsackievirus B3-induced cytopathic effect in HeLa cells. J. Virol. 72:7669.
84. Colston, J. T., B. Chandrasekar, and G. L. Freeman. 1998. Expression of apoptosis-related proteins in experimental Coxsackievirus myocarditis. Cardiovasc. Res. 38:158.
85. Li, J., T. R. Billiar, R. V. Talanian, and Y. M. Kim. 1997. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem. Biophys. Res. Commun. 240:419.
86. Mannick, J. B., X. Q. Miao, and J. S. Stamler. 1997. Nitric oxide inhibits Fas-induced apoptosis. J. Biol. Chem. 272:24125.
87. Mannick, J. B., A. Hausladen, L. Liu, D. T. Hess, M. Zeng, Q. X. Miao, L. S. Kane, A. J. Gow, and J. S. Stamler. 1999. Fas-induced caspase denitrosylation. Science 284:651.
88. Curran, R. D., F. K. Ferrari, P. H. Kispert, J. Stadler, D. J. Stuehr, R. L. Simmons, and T. R. Billiar. 1991. Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis. FASEB J. 5:2085.
89. Toskes, P. P., and N. J. Greenberger. 1996. Approach to the patient with pancreatic disease. In Harrison's Principles of Internal Medicine. K. J. Isselbacher, J. B. Martin, E. Braunwald, J. W. Wilson, A. S. Fauci, and D. L. Kasper, eds. McGraw-Hill, New York, p. 1516.
90. Herskowitz, A., K. W. Beisel, L. J. Wolfgram, and N. R. Rose. 1985. Coxsackievirus B3 murine myocarditis: wide pathologic spectrum in genetically defined inbred strains. Hum. Pathol. 16:671.
91. Gauntt, C. J., M. D. Trousdale, D. R. LaBadie, R. E. Paque, and T. Nealon. 1979. Properties of Coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J. Med. Virol. 3:207.
92. Herskowitz, A., L. J. Wolfgram, N. R. Rose, and K. W. Beisel. 1987. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains. J. Am. Coll. Cardiol. 9:1311.
93. + T cells regulate major histocompatibility complex class II (IA and IE)-dependent susceptibility to Coxsackievirus B3-induced autoimmune myocarditis. J. Virol. 73:5630.
94. Gomez, R. M., X. Cui, C. G. Castagnino, and M. I. Berria. 1993. Differential behavior in pancreas and heart of two Coxsackievirus B3 variants. Intervirology 36:153.
95. Zaragoza, C., M. Saura, F. Y. Liew, S. Moncada, and C. J. Lowenstein. 1998. The role of NOS2 in Coxsackievirus myocarditis. Proc. Natl. Acad. Sci. USA 95:2469.